Print Handheld Contrast

Active Clinical Trials

LONDON:

UWO Urology Research

London Regional Cancer Program

ONTARIO:

Ontario Cancer Trials

Educational Video (NCIC PR.11): A Phase III study of active surveillance therapy against radical treatment in patients diagnosed with favourable risk prostate cancer (START)

 

The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a research study to determine if selenium and vitamin E can help prevent prostate cancer. SELECT is funded by the National Cancer Institute and coordinated by the Southwest Oncology Group.

New Information - October 29, 2008

Important new findings from this study have resulted in a decision by the study leadership to discontinue study supplements, selenium and vitamin E.  The data to date show that 200 mcg of selenium and 400 IUs daily of vitamin E do not prevent prostate cancer.

However, the SELECT study is not over. All study visits will continue as usual and we encourage our participants to continue followup. Your continued participation in prostate cancer surveillance will provide important information regarding prostate cancer's natural history.

We would like to thank all study participants.

Joseph Chin, MD, FRCSC Head of Surgical Oncology Urologic Oncology London Health Sciences Centre Tel: 519-685-8500 ext 58451

Eric Winquist, MD, FRCPC Medical Oncologist London Regional Cancer Program London Health Sciences Centre Tel: 519-685-8500 ext 58640

For more information go to the official SELECT website

The London location is at:

London Prostate Cancer Centre,
Galleria London
355 Wellington Rd Unit 169
London, ON N6A 3N7
Ph:(519) 685-8448
Fax: (519) 685-8516